BiotechTube
Home/Ocuvex Therapeutics/Anthony W. Amato
AW

Anthony W. Amato

Chairman and Chief Executive Officer

Ocuvex Therapeutics

Therapeutic Areas

OphthalmologyGlaucomaPost-Surgical Care

Ocuvex Therapeutics Pipeline

DrugIndicationPhase
OMLONTI®Glaucoma (Intraocular Pressure Reduction)Approved
Undisclosed Pipeline AssetsOcular Diseases (e.g., Post-Surgical Inflammation/Pain)Late Clinical Stage